[Budd-Chiari syndrome in DTIC therapy]

Area of Science:

• Oncology
• Hematology
• Toxicology

Background:

• Malignant melanoma is a serious skin cancer.
• Dacarbazine (DTIC) is a chemotherapy agent used for melanoma.
• Budd-Chiari syndrome is a rare but severe hepatic vascular condition.

Observation:

• A patient with malignant melanoma experienced sudden hepatic vein thrombosis (Budd-Chiari syndrome) after dacarbazine treatment.
• The complication occurred during the second cycle of chemotherapy.
• Blood eosinophil counts increased concurrently with the adverse event.

Findings:

• Increasing blood eosinophilia was observed preceding the fatal outcome.
• This suggests a potential link between eosinophilia and dacarbazine-induced Budd-Chiari syndrome.
• The patient's rapid deterioration and death highlight the severity of this complication.

Implications:

• Blood eosinophil monitoring could aid in early detection of dacarbazine toxicity.
• This case underscores the need for vigilance regarding rare but severe chemotherapy side effects.
• Further research may elucidate the mechanisms of dacarbazine-induced vascular complications.